Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.

@article{Burstein2005EfficacyOP,
  title={Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.},
  author={Harold J. Burstein and Leroy Monroe Parker and Aparna Keshaviah and Jennifer K Doherty and Ann Partridge and Lidia Schapira and Paula D Ryan and Jerry Younger and Lyndsay N. Harris and Beverly Moy and Steven E. Come and Susan Tinsley Schumer and Craig A. Bunnell and Margaret Haldoupis and Rebecca S. Gelman and Eric P. Winer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 33},
  pages={8340-7}
}
PURPOSE Dose-dense, every-2-week adjuvant chemotherapy using doxorubicin/cyclophosphamide (AC; 60/600 mg/m2 every 2 weeks x four cycles) followed by paclitaxel (175 mg/m2 every 2 weeks x four cycles), requiring filgrastim on days 3 through 10 of each cycle has been shown to improve survival compared with every-3-week treatment schedules but is associated with greater risk of RBC transfusion (13%). The role of long-acting hematopoietic growth factors in facilitating every-2-week chemotherapy and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…